Explore
Search
Learn
Watch
Portfolio
ANL
Adlai Nortye Ltd.
Healthcare
$10.59
+542%
1Y
$10.59
$0.88
52 weeks
$16.60
ANL
Adlai Nortye Ltd.
$10.59
+541.82%
1Y
Overview
RyuScore
Safety
Valuation
Market
Financials
More
The financials
Adlai Nortye Ltd. by the numbers
For the full year FY2025, revenue was $5.0M and net income −$36M.
More on Adlai Nortye Ltd.
ANL overview
Price, RyuScore, the earnings flow and the five questions at a glance.
ANL financial charts
Every reported figure as its own chart, quarterly and trailing twelve months.
Is ANL financially safe?
Distress and accounting checks, debt cover, drawdowns and factor exposure.
Is ANL overvalued?
What the price assumes, its own history, peer multiples and a fair-value range.
ANL price history
Trend and momentum, key levels, total return, seasonality.
Who owns ANL?
The quarterly 13F record, and what 13F filings cannot tell you.
ANL SEC filings and events
The company's own record, every flag beside its market-wide base rate.
Biotechnology
Ranks
#177
of 194 by RyuScore
Compare peers
Random peer
JANX
-2.4%
Janux Therapeutics, Inc.
MLTX
-3.8%
MoonLake Immunotherapeutics
MNKD
-0.62%
MannKind Corporation
AVBP
+9.3%
ArriVent BioPharma, Inc.
IMTX
-2.9%
Immatics N.V.
YDES
+18%
YD Bio Ltd